Thermo Fisher Scientific announced plans to establish a manufacturing facility in Nashville dedicated to the production of single-use technologies (SUT) products. This investment is in addition to the previously announced expansion to address unprecedented demand in the bioprocessing market. The facility will be one of the world's largest SUT manufacturing sites and will more than double the company's SUT manufacturing capacity in support of its biopharma customers. Construction will begin in summer 2022.
"Over the last few years, more and more biological drugs and vaccines are being manufactured utilizing the single use platform. This has created incredible demand for our SUT products," said Michel Lagarde, executive vice president of Thermo Fisher Scientific. "The site in Nashville will be critical in Thermo Fisher's global network to continue to support the biopharma industry's work in developing life-saving biologics and vaccines."
The Nashville site is part of Thermo Fisher's now more than $650 million capital investment to expand its bioprocessing production capabilities across 11 manufacturing sites in North America, Europe and Asia. Additional capacity will be added in 2021 with the completion of expansion projects in Logan, Utah, Suzhou, China, and a new SUT manufacturing site in Singapore. This additional capacity in the SUT network supports global customers as the company's manufacturing strategy utilizes equivalent processes and procedures to manufacture SUT products of consistent quality, form, fit and function worldwide.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!